|Trade names||Largactil, Thorazine, others|
|Oral (tablets and syrup available), rectal, IM, IV infusion|
|ATC code||N05AA01 (WHO)|
|Bioavailability||10–80% (Oral; large interindividual variation)|
|Metabolism||Liver, mostly CYP2D6-mediated|
|Biological half-life||30 hours|
|Excretion||Urine (43–65% in 24 hrs)|
|CAS Number||50-53-3 (free base)
|Chemical and physical data|
|Molar mass||318.86 g/mol (free base)
355.33 g/mol (hydrochloride)
|3D model (Jmol)||Interactive image|
Chlorpromazine (CPZ), marketed under the trade names Thorazine and Largactil among others, is an antipsychotic medication. It is primarily used to treat psychotic disorders such as schizophrenia. Other uses include the treatment of bipolar disorder, attention deficit hyperactivity disorder, nausea and vomiting, anxiety before surgery, and hiccups that do not improve following other measures. It can be given by mouth, by injection into a muscle, or into a vein.
Common side effects include movement problems, sleepiness, dry mouth, low blood pressure upon standing, and increased weight. Serious side effects may include the potentially permanent movement disorder tardive dyskinesia, neuroleptic malignant syndrome, and low white blood cell levels. In older people with psychosis as a result of dementia it may increase the risk of dying. It is unclear if it is safe for use in pregnancy. Chlorpromazine is in the typical antipsychotic class. Its mechanism of action is not entirely clear but believed to be related to its ability as a dopamine antagonist. It also has anti-serotonergic and antihistaminergic properties.
Chlorpromazine was discovered in 1950 and was the first antipsychotic. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. Its introduction has been labeled as one of the great advances in the history of psychiatry. It is available as a generic medication. The wholesale cost in the developing world is between US$0.02 and US$0.12 per day. In the United States it costs about US$2 per day.
Chlorpromazine is classified as a low-potency typical antipsychotic and in the past was used in the treatment of both acute and chronic psychoses, including schizophrenia and the manic phase of bipolar disorder, as well as amphetamine-induced psychoses. Low-potency antipsychotics have more anticholinergic side effects, such as dry mouth, sedation, and constipation, and lower rates of extrapyramidal side effects, while high-potency antipsychotics (such as haloperidol) have the reverse profile.
Chlorpromazine has also been used in porphyria and as part of tetanus treatment. It still is recommended for short-term management of severe anxiety and psychotic aggression. Resistant and severe hiccups, severe nausea/emesis, and preanesthetic conditioning are other uses. Symptoms of delirium in medically-hospitalized AIDS patients have been effectively treated with low doses of chlorpromazine.
Chlorpromazine is occasionally used off-label for treatment of severe migraine. It is often, particularly as palliation, used in small doses to reduce nausea suffered by opioid-treated cancer patients and to intensify and prolong the analgesia of the opioids as well.
|Measured outcome||Findings in words||Findings in numbers||Quality of evidence|
|Not any improvement (9 weeks – 6 months)||30% less risk of having no improvement in mental state, behaviour and functioning||RR 0.7 CI 0.6 to 0.9||Very low (estimate of effect uncertain)|
|Relapse (6 months – 2 years)||35% less risk of relapse||RR 0.7 CI 0.5 to 0.9|
There appears to be a dose-dependent risk for seizures with chlorpromazine treatment. Tardive dyskinesia and akathisia are less commonly seen with chlorpromazine than they are with high potency typical antipsychotics such as haloperidol or trifluoperazine, and some evidence suggests that, with conservative dosing, the incidence of such effects for chlorpromazine may be comparable to that of newer agents such as risperidone or olanzapine.
Chlorpromazine may deposit in ocular tissues when taken in high dosages for long periods of time.
|Measured outcome||Findings in words||Findings in numbers||Quality of evidence|
|Weight gain||5 times more likely to have considerable weight gain, around 40% with chlorpromazine gaining weight||RR 4.9 CI 2.3 to 10.4||Very low (estimate of effect uncertain)|
|Sedation||3 times more likely to cause sedation, around 30% with chlorpromazine||RR 2.8 CI 2.3 to 3.5|
|Acute movement disorder||3.5 times more likely to cause easily reversible but unpleasant severe stiffening of muscles, around 6% with chlorpromazine||RR 3.5 CI 1.5 to 8.0|
|Parkinsonism||2 times more likely to cause parkinsonism (symptoms such as tremor, hesitancy of movement, decreased facial expression), around 17% with chlorpromazine||RR 2.1 CI 1.6 to 2.8|
|Decreased blood pressure with dizziness||3 times more likely to cause decreased blood pressure and dizziness, around 15% with chlorpromazine||RR 2.4 CI 1.7 to 3.3|
Absolute contraindications include:
- Previous hypersensitivity (including jaundice, agranulocytosis, etc.) to phenothiazines, especially chlorpromazine, or any of the excipients in the formulation being used.
Relative contraindications include:
Very rarely, elongation of the QT interval may occur, increasing the risk of potentially fatal arrhythmias.
Consuming food prior to taking chlorpromazine orally limits its absorption, likewise cotreatment with benztropine can also reduce chlorpromazine absorption. Alcohol can also reduce chlorpromazine absorption. Antacids slow chlorpromazine absorption. Lithium and chronic treatment with barbiturates can increase chlorpromazine clearance significantly. Tricyclic antidepressants (TCAs) can decrease chlorpromazine clearance and hence increase chlorpromazine exposure. Cotreatment with CYP1A2 inhibitors like ciprofloxacin, fluvoxamine or vemurafenib can reduce chlorpromazine clearance and hence increase exposure and potentially also adverse effects. Chlorpromazine can also potentiate the CNS depressant effects of drugs like barbiturates, benzodiazepines, opioids, lithium and anaesthetics and hence increase the potential for adverse effects such as respiratory depression and sedation.
It is also a moderate inhibitor of CYP2D6 and also a substrate for CYP2D6 and hence can inhibit its own metabolism. It can also inhibit the clearance of CYP2D6 substrates such as dextromethorphan and hence also potentiate their effects. Other drugs like codeine and tamoxifen which require CYP2D6-mediated activation into their respective active metabolites may have their therapeutic effects attenuated. Likewise CYP2D6 inhibitors such as paroxetine or fluoxetine can reduce chlorpromazine clearance and hence increase serum levels of chlorpromazine and hence potentially also its adverse effects. Chlorpromazine also reduces phenytoin levels and increases valproic acid levels. It also reduces propranolol clearance and antagonises the therapeutic effects of antidiabetic agents, levodopa (a Parkinson's medication. This is likely due to the fact that chlorpromazine antagonises the D2 receptor which is one of the receptors dopamine, a levodopa metabolite, activates), amfetamines and anticoagulants. It may also interact with anticholinergic drugs such as orphenadrine to produce hypoglycaemia (low blood sugar).
Chlorpromazine may also interact with epinephrine (adrenaline) to produce a paradoxical fall in blood pressure. Monoamine oxidase inhibitors (MAOIs) and thiazide diuretics may also accentuate the orthostatic hypotension experienced by those receiving chlorpromazine treatment. Quinidine may interact with chlorpromazine to increase myocardialdepression. Likewise it may also antagonise the effects of clonidine and guanethidine. It also may reduce the seizure threshold and hence a corresponding titration of anticonvulsant treatments should be considered. Prochlorperazine and desferrioxamine may also interact with chlorpromazine to produce transient metabolic encephalopathy.
Tolerance and withdrawal
The British National Formulary recommends a gradual withdrawal when discontinuing antipsychotic treatment to avoid acute withdrawal syndrome or rapid relapse. While withdrawal symptoms can occur, there is no evidence that tolerance develops to the drug's antipsychotic effects. A patient can be maintained for years on a therapeutically effective dose without any decrease in effectiveness being reported. Tolerance appears to develop to the sedating effects of chlorpromazine when it is first administered. Tolerance also appears to develop to the extrapyramidal, parkinsonian and other neuroleptic effects, although this is debatable.
A failure to notice withdrawal symptoms may be due to the relatively long half life of the drug resulting in the extremely slow excretion from the body. However, there are reports of muscular discomfort, exaggeration of psychotic symptoms and movement disorders, and difficulty sleeping when the antipsychotic drug is suddenly withdrawn, but after years of normal doses these effects are not normally seen.
|Bioavailability||tmax||CSS||Protein bound||Vd||t1/2||Details of metabolism||Excretion||Notes|
|10–80%||1–4 hours (Oral); 6–24 hours (IM)||100–300 ng/mL||90–99%||10–35 L/kg (mean: 22 L/kg)||30±7 hours||CYP2D6, CYP1A2—mediated into over 10 major metabolites. The major routes of metabolism include hydroxylation, N-oxidation, sulphoxidation, demethylation, deamination and conjugation. There is little evidence supporting the development of metabolic tolerance or an increase in the metabolism of chlorpromazine due to microsomal liver enzymes following multiple doses of the drug.||Urine (43–65% after 24 hours)||Its high degree of lipophilicity (fat solubility) allows it to be detected in the urine for up to 18 months. Less than 1% of the unchanged drug is excreted via the kidneys in the urine, in which 20–70% is excreted as conjugated or unconjugated metabolites, whereas 5–6% is excreted in feces.|
Chlorpromazine is a very effective antagonist of D2 dopamine receptors and similar receptors, such as D3 and D5. Unlike most other drugs of this genre, it also has a high affinity for D1 receptors. Blocking these receptors causes diminished neurotransmitter binding in the forebrain, resulting in many different effects. Dopamine, unable to bind with a receptor, causes a feedback loop that causes dopaminergic neurons to release more dopamine. Therefore, upon first taking the drug, patients will experience an increase in dopaminergic neural activity. Eventually, dopamine production of the neurons will drop substantially and dopamine will be removed from the synaptic cleft. At this point, neural activity decreases greatly; the continual blockade of receptors only compounds this effect.
Chlorpromazine acts as an antagonist (blocking agent) on different postsynaptic and presynaptic receptors:
- Dopamine receptors (subtypes D1, D2, D3 and D4), which account for its different antipsychotic properties on productive and unproductive symptoms, in the mesolimbic dopamine system accounts for the antipsychotic effect whereas the blockade in the nigrostriatal system produces the extrapyramidal effects
- Serotonin receptors (5-HT1 and 5-HT2), with anxiolytic, and antiaggressive properties as well as an attenuation of extrapyramidal side effects, but also leading to weight gain and ejaculation difficulties.
- Histamine receptors (H1 receptors, accounting for sedation, antiemetic effect, vertigo, and weight gain)
- α1- and α2-adrenergic receptors (accounting for sympatholytic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism—controversial. Also associated with weight gain as a result of blockage of the adrenergic alpha 1 receptor)
- M1 and M2 muscarinic acetylcholine receptors (causing anticholinergic symptoms such as dry mouth, blurred vision, constipation, difficulty or inability to urinate, sinus tachycardia, electrocardiographic changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side effects).
The presumed effectiveness of the antipsychotic drugs relied on their ability to block dopamine receptors. This assumption arose from the dopamine hypothesis that maintains that both schizophrenia and bipolar disorder are a result of excessive dopamine activity. Furthermore, psychomotor stimulants like cocaine that increase dopamine levels can cause psychotic symptoms if taken in excess.
Chlorpromazine and other typical antipsychotics are primarily blockers of D2 receptors. In fact an almost perfect correlation exists between the therapeutic dose of a typical antipsychotic and the drug's affinity for the D2 receptor. Therefore, a larger dose is required if the drug’s affinity for the D2 receptor is relatively weak. A correlation exists between average clinical potency and affinity of the antipsychotics for dopamine receptors. Chlorpromazine tends to have greater effect at serotonin receptors than at D2 receptors, which is notably the opposite effect of the other typical antipsychotics. Therefore, chlorpromazine with respect to its effects on dopamine and serotonin receptors is more similar to the atypical antipsychotics than to the typical antipsychotics.
Chlorpromazine and other antipsychotics with sedative properties such as promazine and thioridazine are among the most potent agents at α-adrenergic receptors. Furthermore, they are also among the most potent antipsychotics at histamine H1 receptors. This finding is in agreement with the pharmaceutical development of chlorpromazine and other antipsychotics as anti-histamine agents. Furthermore, the brain has a higher density of histamine H1 receptors than any body organ examined which may account for why chlorpromazine and other phenothiazine antipsychotics are as potent at these sites as the most potent classical antihistamines.
In addition to influencing the neurotransmitters dopamine, serotonin, epinephrine, norepinephrine, and acetylcholine it has been reported that antipsychotic drugs could achieve glutamanergic effects. This mechanism involves direct effects on antipsychotic drugs on glutamate receptors. By using the technique of functional neurochemical assay chlorpromazine and phenothiazine derivatives have been shown to have inhibitory effects on NMDA receptors that appeared to be mediated by action at the Zn site. It was found that there is an increase of NMDA activity at low concentrations and suppression at high concentrations of the drug. No significant difference in glutamate and glycine activity from the effects of chlorpromazine were reported. Further work will be necessary to determine if the influence in NMDA receptors by antipsychotic drugs contributes to their effectiveness.
Chlorpromazine is an antagonist to H1 receptors (provoking antiallergic effects), H2 receptors (reduction of forming of gastric juice), M1 and M2 receptors (dry mouth, reduction in forming of gastric juice) and some 5-HT receptors (different anti-allergic/gastrointestinal actions).
In 1933, the French pharmaceutical company Laboratoires Rhône-Poulenc began to search for new anti-histamines. In 1947, it synthesized promethazine, a phenothiazine derivative, which was found to have more pronounced sedative and antihistaminic effects than earlier drugs. A year later, the French surgeon Pierre Huguenard used promethazine together with pethidine as part of a cocktail to induce relaxation and indifference in surgical patients. Another surgeon, Henri Laborit, believed the compound stabilized the central nervous system by causing "artificial hibernation", and described this state as "sedation without narcosis". He suggested to Rhône-Poulenc that they develop a compound with better stabilizing properties. In December 1950, the chemist Paul Charpentier produced a series of compounds that included RP4560 or chlorpromazine. Simone Courvoisier conducted behavioural tests and found chlorpromazine produced indifference to aversive stimuli in rats. Chlorpromazine was distributed for testing to physicians between April and August 1951. Laborit trialled the medicine on at the Val-de-Grâce military hospital in Paris, using it as an anaesthetic booster in intravenous doses of 50 to 100 mg on surgery patients and confirming it as the best drug to date in calming and reducing shock, with patients reporting improved well being afterwards. He also noted its hypothermic effect and suggested it may induce artificial hibernation. Laborit thought this would allow the body to better tolerate major surgery by reducing shock, a novel idea at the time. Known colloquially as "Laborit's drug", chlorpromazine was released onto the market in 1953 by Rhône-Poulenc and given the trade name Largactil, derived from large "broad" and acti* "activity.
Following on, Laborit considered whether chlorpromazine may have a role in managing patients with severe burns, Raynaud's phenomenon, or psychiatric disorders. At the Villejuif Mental Hospital in November 1951, he and Montassut administered an intravenous dose to psychiatrist Cornelia Quarti who was acting as a volunteer. Quarti noted the indifference, but fainted upon getting up to go to the toilet, and so further testing was discontinued (orthostatic hypotension is a possible side effect of chlorpromazine). Despite this, Laborit continued to push for testing in psychiatric patients during early 1952. Psychiatrists were reluctant initially, but on January 19, 1952, it was administered (alongside pethidine, pentothal and ECT) to Jacques Lh. a 24-year-old manic patient, who responded dramatically, and was discharged after three weeks having received 855 mg of the drug in total.
Pierre Deniker had heard about Laborit's work from his brother-in-law, who was a surgeon, and ordered chlorpromazine for a clinical trial at the Hôpital Sainte-Anne in Paris where he was Men's Service Chief. Together with the Director of the hospital, Professor Jean Delay, they published their first clinical trial in 1952, in which they treated 38 psychotic patients with daily injections of chlorpromazine without the use of other sedating agents. The response was dramatic; treatment with chlorpromazine went beyond simple sedation with patients showing improvements in thinking and emotional behaviour. They also found that doses higher than those used by Laborit were required, giving patients 75–100 mg daily.
Deniker then visited America, where the publication of their work alerted the American psychiatric community that the new treatment might represent a real breakthrough. Heinz Lehmann of the Verdun Protestant Hospital in Montreal trialled it in 70 patients and also noted its striking effects, with patients' symptoms resolving after many years of unrelenting psychosis. By 1954, chlorpromazine was being used in the United States to treat schizophrenia, mania, psychomotor excitement, and other psychotic disorders. Rhône-Poulenc licensed chlorpromazine to Smith Kline & French (today's GlaxoSmithKline) in 1953. In 1955 it was approved in the United States for the treatment of emesis (vomiting). The effect of this drug in emptying psychiatric hospitals has been compared to that of penicillin and infectious diseases. But the popularity of the drug fell from the late 1960s as newer drugs came on the scene. From chlorpromazine a number of other similar antipsychotics were developed. It also led to the discovery of antidepressants.
Chlorpromazine largely replaced electroconvulsive therapy, hydrotherapy, psychosurgery, and insulin shock therapy. By 1964, about 50 million people worldwide had taken it. Chlorpromazine, in widespread use for 50 years, remains a "benchmark" drug in the treatment of schizophrenia, an effective drug although not a perfect one. The relative strengths or potencies of other antipsychotics are often ranked or measured against chlorpromazine in aliquots of 100 mg, termed chlorpromazine equivalents or CPZE.
|This section needs additional citations for verification. (January 2017) (Learn how and when to remove this template message)|
It is commonly used to decrease nausea in animals that are too young for other common anti-emetics. It is also sometimes used as a preanesthetic and muscle relaxant in cattle, swine, sheep, and goats.
- "PRODUCT INFORMATION LARGACTIL" (PDF). TGA eBusiness Services. Sanofi Aventis Pty Ltd. 28 August 2012. Retrieved 8 December 2013.
- "Chlorpromazine Hydrochloride". The American Society of Health-System Pharmacists. Retrieved Dec 1, 2015.
- López-Muñoz, Francisco; Alamo, Cecilio; Cuenca, Eduardo; Shen, Winston W.; Clervoy, Patrick; Rubio, Gabriel (2005). "History of the discovery and clinical introduction of chlorpromazine". Annals of Clinical Psychiatry. 17 (3): 113–35. doi:10.1080/10401230591002002. PMID 16433053.
- Ban, TA (August 2007). "Fifty years chlorpromazine: a historical perspective.". Neuropsychiatric disease and treatment. 3 (4): 495–500. PMC . PMID 19300578.
- "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Retrieved 8 December 2016.
- López-Muñoz, F; Alamo, C; Cuenca, E; Shen, WW; Clervoy, P; Rubio, G (2005). "History of the discovery and clinical introduction of chlorpromazine.". Annals of Clinical Psychiatry. 17 (3): 113–35. doi:10.1080/10401230591002002. PMID 16433053.
- Shorter, Edward (2005). A historical dictionary of psychiatry. New York: Oxford University Press. p. 6. ISBN 9780198039235.
- "Chlorpromazine HCL". International Drug Price Indicator Guide. Retrieved 1 December 2015.
- Brunton, L; Chabner, B; Knollman, B (2010). Goodman and Gilman's The Pharmacological Basis of Therapeutics (12th ed.). New York: McGraw-Hill Professional. ISBN 978-0-07-162442-8.
- American Society of Health-System Pharmacists (November 1, 2008). "Chlorpromazine". PubMed Health. National Center for Biotechnology Information.
- Breitbart, W; Marotta, R; Platt, MM; et al. (February 1996). "A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients". The American Journal of Psychiatry. 153 (2): 231–7. doi:10.1176/ajp.153.2.231. PMID 8561204.
- Chlorpromazine. Martindale: The Complete Drug Reference. London: Pharmaceutical Press. 30 January 2013. Retrieved 8 December 2013.
- Logan, Peter; Lewis, David (April 2007). "Chlorpromazine in Migraine" (PDF). Emergency Medicine Journal. 24 (4): 297–300. doi:10.1136/emj.2007.047860. PMC . PMID 17384391.
- Richter, PA; Burk, MP (July–August 1992). "The potentiation of narcotic analgesics with phenothiazines". The Journal of Foot Surgery. 31 (4): 378–380. PMID 1357024.
- "Propaphenin, Medicine and Disease information". EPG Online. 2001-07-14. Retrieved 26 November 2013.
- Adams CE, Awad G, Rathbone J, Thornley B, Soares-Weiser K (2014). "Chlorpromazine versus placebo for schizophrenia". Cochrane Database of Systematic Reviews. 1 (1): CD000284. doi:10.1002/14651858.CD000284.pub3. PMID 24395698.
- Pisani, F; Oteri, G; Costa, C; Di Raimondo, G; Di Perri, R (2002). "Effects of psychotropic drugs on seizure threshold". Drug Safety. 25 (2): 91–110. doi:10.2165/00002018-200225020-00004. PMID 11888352.
- Leucht C, Kitzmantel M, Chua L, Kane J, Leucht S (2008). Leucht, Claudia, ed. "Haloperidol versus chlorpromazine for schizophrenia". Cochrane Database of Systematic Reviews (1): CD004278. doi:10.1002/14651858.CD004278.pub2. PMID 18254045.
- Leucht S, Wahlbeck K, Hamann J, Kissling W (May 2003). "New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis". Lancet. 361 (9369): 1581–9. doi:10.1016/S0140-6736(03)13306-5. PMID 12747876.
- Thomas D; Wu K; Kathöfer S; et al. (June 2003). "The antipsychotic drug chlorpromazine inhibits HERG potassium channels". British Journal of Pharmacology. 139 (3): 567–74. doi:10.1038/sj.bjp.0705283. PMC . PMID 12788816.
- Joint Formulary Committee (2013). British National Formulary (BNF) (65 ed.). London, UK: Pharmaceutical Press. ISBN 978-0-85711-084-8.
- McKim, William A. (2007). Drugs and behavior: an introduction to behavioral pharmacology (6th ed.). Upper Saddle River, New Jersey: Prentice Hall. p. 416. ISBN 978-0-13-219788-5.
- "Chlorpromazine Hydrochloride 100mg/5ml Oral Syrup - Summary of Product Characteristics (SPC)". electronic Medicines Compendium. Rosemont Pharmaceuticals Limited. 6 August 2013. Retrieved 8 December 2013.
- Dahl SG, Strandjord RE (April 1977). "Pharmacokinetics of chlorpromazine after single and chronic dosage". Clinical Pharmacology and Therapeutics. 21 (4): 437–48. PMID 849674.
- Yeung PK, Hubbard JW, Korchinski ED, Midha KK (1993). "Pharmacokinetics of chlorpromazine and key metabolites". European Journal of Clinical Pharmacology. 45 (6): 563–9. doi:10.1007/BF00315316. PMID 8157044.
- Girault J, Greengard P (2004). "The neurobiology of dopamine signaling". Arch Neurol. 61 (5): 641–44. doi:10.1001/archneur.61.5.641. PMID 15148138.
- Peroutka SJ, Synder SH (December 1980). "Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency". The American Journal of Psychiatry. 137 (12): 1518–22. PMID 6108081.
- Lidsky TI, Yablonsky-Alter E, Zuck LG, Banerjee SP (August 1997). "Antipsychotic drug effects on glutamatergic activity". Brain Research. 764 (1–2): 46–52. doi:10.1016/S0006-8993(97)00423-X. PMID 9295192.
- Kornhuber J, Muehlbacher M, Trapp S, Pechmann S, Friedl A, Reichel M, Mühle C, Terfloth L, Groemer T, Spitzer G, Liedl K, Gulbins E, Tripal P (2011). Riezman, Howard, ed. "Identification of novel functional inhibitors of acid sphingomyelinase". PLoS ONE. 6 (8): e23852. doi:10.1371/journal.pone.0023852. PMC . PMID 21909365.
- Falkai, P; Vogeley K (April 2000). "The chances of new atypical substances". biopsychiatry.com. Retrieved 6 July 2010.
- "Thorazine advertisement". Smith Kline & French. c. 1963.
When the patient lashes out against 'them' — THORAZINE (brand of chlorpromazine) quickly puts an end to his violent outburst. 'Thorazine' is especially effective when the psychotic episode is triggered by delusions or hallucinations. At the outset of treatment, Thorazine's combination of antipsychotic and sedative effects provides both emotional and physical calming. Assaultive or destructive behavior is rapidly controlled. As therapy continues, the initial sedative effect gradually disappears. But the antipsychotic effect continues, helping to dispel or modify delusions, hallucinations and confusion, while keeping the patient calm and approachable. SMITH KLINE AND FRENCH LABORATORIES leaders in psychopharmaceutical research
- Healy, David (2004). "Explorations in a new world". The creation of psychopharmacology. Harvard University Press. p. 77. ISBN 978-0-674-01599-9. Retrieved 26 November 2013.
- Healy, David (2004). "Explorations in a new world". The creation of psychopharmacology. Harvard University Press. p. 80. ISBN 978-0-674-01599-9.
- Turner, T (January 2007). "Chlorpromazine: unlocking psychosis". BMJ. 334 (Suppl 1): s7. doi:10.1136/bmj.39034.609074.94. PMID 17204765.
- Healy, David (2004). The Creation of Psychopharmacology. Harvard University Press. pp. 37–73. ISBN 978-0-674-01599-9. Retrieved 26 November 2013.
- Long, James W. (1992). The Essential guide to prescription drugs. New York: HarperPerennial. pp. 321–325. ISBN 978-0-06-271534-0.
- Reines, Brandon P (1990). "The Relationship Between Laboratory and Clinical Studies in Psychopharmacologic Discovery". Perspectives on Medical Research. Medical Research Modernization Society. 2. Retrieved 26 November 2013.
- Healy, David (2004). "Introduction". The Creation of Psychopharmacology. Harvard University Press. p. 2. ISBN 9780674015999. Retrieved 26 November 2013.
- Healy, David (2000). "Psychopharmacology and the Government of the Self" (PDF). davidhealy.org. Retrieved 20 July 2015.
- "Drug for treating schizophrenia identified". PBS.org. WGBH-TV. Retrieved 7 July 2010.
- Yorston, G. (2000). "Chlorpromazine equivalents and percentage of British National Formulary maximum recommended dose in patients receiving high-dose antipsychotics". Psychiatric Bulletin. 24 (4): 130–132. doi:10.1192/pb.24.4.130.
- Bangen, Hans (1992). Geschichte der medikamentösen Therapie der Schizophrenie. Verlag für Wissenschaft und Bildung. p. 98. ISBN 3-927-408-82-4.
- Plumb, Donald C. (9 February 2015). Plumb's Veterinary Drug Handbook (8th ed.). John Wiley & Sons. ISBN 111891192X.
- "Chlorpromazine: summary report" (PDF). European Medicines Agency. Committee for Veterinary Medicinal Products. June 1996. Retrieved 2017-01-17.
- Kim, JH; Jung, SY; Lee, YJ; Song, KJ; Kwon, D; Kim, K; Park, S; Im, KI; Shin, HJ (November 2008). "Effect of therapeutic chemical agents in vitro and on experimental meningoencephalitis due to Naegleria fowleri" (PDF). Antimicrobial Agents and Chemotherapy. 52 (11): 4010–4016. doi:10.1128/AAC.00197-08. PMC . PMID 18765686.